- Home
- MIRM vs VKTX Comparison
MIRM vs VKTX Comparison
Compare MIRM & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- VKTX
- Stock Information
- Founded
- MIRM 2018
- VKTX 2012
- Country
- MIRM United States
- VKTX United States
- Employees
- MIRM N/A
- VKTX N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- MIRM Health Care
- VKTX Health Care
- Exchange
- MIRM Nasdaq
- VKTX Nasdaq
- Market Cap
- MIRM 3.3B
- VKTX 3.5B
- IPO Year
- MIRM 2019
- VKTX 2015
- Fundamental
- Price
- MIRM $73.14
- VKTX $23.09
- Analyst Decision
- MIRM Strong Buy
- VKTX Strong Buy
- Analyst Count
- MIRM 10
- VKTX 12
- Target Price
- MIRM $74.20
- VKTX $87.50
- AVG Volume (30 Days)
- MIRM 679.0K
- VKTX 6.8M
- Earning Date
- MIRM 11-11-2025
- VKTX 10-22-2025
- Dividend Yield
- MIRM N/A
- VKTX N/A
- EPS Growth
- MIRM N/A
- VKTX N/A
- EPS
- MIRM N/A
- VKTX N/A
- Revenue
- MIRM $429,161,000.00
- VKTX N/A
- Revenue This Year
- MIRM $53.08
- VKTX N/A
- Revenue Next Year
- MIRM $20.45
- VKTX N/A
- P/E Ratio
- MIRM N/A
- VKTX N/A
- Revenue Growth
- MIRM 62.33
- VKTX N/A
- 52 Week Low
- MIRM $36.86
- VKTX $18.92
- 52 Week High
- MIRM $78.10
- VKTX $81.73
- Technical
- Relative Strength Index (RSI)
- MIRM 58.57
- VKTX 32.25
- Support Level
- MIRM $73.35
- VKTX $24.82
- Resistance Level
- MIRM $74.99
- VKTX $26.50
- Average True Range (ATR)
- MIRM 2.37
- VKTX 1.18
- MACD
- MIRM -0.94
- VKTX -0.20
- Stochastic Oscillator
- MIRM 20.40
- VKTX 2.47
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.